

# Judith Straimer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11130283/publications.pdf>

Version: 2024-02-01

18  
papers

2,518  
citations

471509

17  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2697  
citing authors

#	ARTICLE	IF	CITATIONS
1	High Prevalence of <i>Plasmodium falciparum</i> K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine. <i>Journal of Infectious Diseases</i> , 2022, 225, 1411-1414.	4.0	54
2	Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Clinical Infectious Diseases</i> , 2022, 74, 1831-1839.	5.8	21
3	<i>Plasmodium falciparum</i> K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. <i>ELife</i> , 2021, 10, .	6.0	85
4	Insights into the intracellular localization, protein associations and artemisinin resistance properties of <i>Plasmodium falciparum</i> K13. <i>PLoS Pathogens</i> , 2020, 16, e1008482.	4.7	60
5	Generation of Transmission-Competent Human Malaria Parasites with Chromosomally-Integrated Fluorescent Reporters. <i>Scientific Reports</i> , 2019, 9, 13131.	3.3	22
6	Artemisinin resistance phenotypes and K13 inheritance in a <i>Plasmodium falciparum</i> cross and <i>Aotus</i> model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12513-12518.	7.1	46
7	<i>Plasmodium falciparum</i> K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness <i>In Vitro</i> . <i>MBio</i> , 2017, 8, .	4.1	103
8	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017, 8, 15159.	12.8	51
9	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. <i>PLoS Medicine</i> , 2016, 13, e1002138.	8.4	35
10	Globally prevalent PfMDR1 mutations modulate <i>Plasmodium falciparum</i> susceptibility to artemisinin-based combination therapies. <i>Nature Communications</i> , 2016, 7, 11553.	12.8	208
11	A Worldwide Map of <i>Plasmodium falciparum</i> K13-Propeller Polymorphisms. <i>New England Journal of Medicine</i> , 2016, 374, 2453-2464.	27.0	449
12	Artemisinin Action and Resistance in <i>Plasmodium falciparum</i> . <i>Trends in Parasitology</i> , 2016, 32, 682-696.	3.3	271
13	Balancing drug resistance and growth rates via compensatory mutations in the <i>Plasmodium falciparum</i> chloroquine resistance transporter. <i>Molecular Microbiology</i> , 2015, 97, 381-395.	2.5	47
14	Targeting the Cell Stress Response of <i>Plasmodium falciparum</i> to Overcome Artemisinin Resistance. <i>PLoS Biology</i> , 2015, 13, e1002132.	5.6	254
15	K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates. <i>Science</i> , 2015, 347, 428-431.	12.6	563
16	Editing the <i>Plasmodium vivax</i> Genome, Using Zinc-Finger Nucleases. <i>Journal of Infectious Diseases</i> , 2015, 211, 125-129.	4.0	25
17	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in <i>Plasmodium falciparum</i> in Kenya. <i>Scientific Reports</i> , 2013, 3, 3318.	3.3	75
18	Site-specific genome editing in <i>Plasmodium falciparum</i> using engineered zinc-finger nucleases. <i>Nature Methods</i> , 2012, 9, 993-998.	19.0	149